Search
Now showing items 21-30 of 447
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
(2009)
Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...
Switching benchmarks in cancer of unknown primary: From autopsy to microarray
(2007)
Introduction: Cancer of unknown primary (CUP) is associated with unknown biology and dismal prognosis. Information on the primary site of origin is scant and has never been analysed. We systematically reviewed all published ...
Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature
(2008)
Aim: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the ...
Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade
(2012)
Introduction: The comparison of clinical cancer research characteristics across the Atlantic and their evolution over time have not been studied to date. Methods: We collected oral presentations on breast, lung and colorectal ...
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: Incidence, correlations and prognostic utility
(2012)
Background: The epithelial to mesenchymal transition (EMT) has been associated with metastatic dissemination and poor outcome in several solid tumour types. Our aim was to study its incidence and its prognostic significance ...
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
(2005)
Background: Interest in the use of preoperative systemic treatment in the management of breast cancer has increased because such neoadjuvant therapy appears to reduce the extent of local surgery required. We compared the ...
The current and future role of the medical oncologist in the professional care for cancer patients: A position paper by the European Society for Medical Oncology (ESMO)
(2014)
The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly ...
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group
(1997)
37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There ...